UCSD CIT – Actively Enrolling Trials

SLE

  • Anifrolumab (anti-INFr mAb); 2 studies, in renal and non-renal SLE
  • NIH sponsored MMF withdrawal study (SLE patients stable on MMF)
  • Anti-CD19 mAb in active, non-renal SLE 
  • Abatacept in SLE with arthritis
  • Baricitnib (jakinib) 2 studies in renal and non-renal SLE 
  • RNAase-Fc fusion protein for lupus skin disease

Rheumatoid Arthritis (RA)

  •  - 3 studies of a new jakinib (filgotinib), all followed by open label extension
  • - MTX-naïve
  • - MTX incomplete responder
  • - TNFi exposed
  • - Rituximab vs rituximab biosimilar; open label treatment available!

Psoriatic Arthritis 

  • Anti-IL-17A mAb (secukinumab) in PsA (TNFi naïve); open label extension!
  • Anti-IL-17A/F mAb (bimekizumab) in AS; TNFi failure allowed; open label extension!

Ankylosing Spondylitis (AS)

  • Anti-IL-17A/F mAb (bimekizumab) in AS; TNFi failure allowed; open label extension!

More New Studies about to start!
For info or to refer a patient, please call 858-246-2387 or e-mail: cit@ucsd.edu, or any of us: 
kkalunian@ucsd.eduakavanaugh@ucsd.edus2lee@ucsd.edu